In lupus-associated nephritis, P2X7 receptor antagonists reduced nephritis severity, pro-inflammatory serum cytokines, and NLRP3 inflammasome activation underlying once more the broad therapeutic potential of these pathways (17). Here, P2RX7 is linked to nephritis.